Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
EXEL Exelixis, Inc. daily Stock Chart
Exelixis, Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own1.69% Shs Outstand225.43M Perf Week0.00%
Market Cap1.33B Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float210.52M Perf Month0.17%
Income-199.00M PEG- EPS next Q-0.20 Inst Own53.10% Short Float26.21% Perf Quarter68.38%
Sales31.00M P/S42.98 EPS this Y-3.80% Inst Trans-1.53% Short Ratio7.32 Perf Half Y115.69%
Book/sh-0.96 P/B- EPS next Y11.10% ROA-64.10% Target Price6.00 Perf Year291.39%
Cash/sh0.37 P/C16.11 EPS next 5Y- ROE156.80% 52W Range1.26 - 6.81 Perf YTD310.42%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-90.80% 52W High-13.22% Beta2.59
Dividend %- Quick Ratio1.50 Sales past 5Y-30.20% Gross Margin91.30% 52W Low369.05% ATR0.40
Employees98 Current Ratio1.50 Sales Q/Q21.20% Oper. Margin- RSI (14)48.25 Volatility8.12% 6.33%
OptionableYes Debt/Eq- EPS Q/Q42.10% Profit Margin- Rel Volume0.60 Prev Close5.73
ShortableYes LT Debt/Eq- EarningsNov 04 AMC Payout- Avg Volume7.54M Price5.91
Recom2.40 SMA20-0.98% SMA501.09% SMA20065.30% Volume4,512,786 Change3.14%
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Aug-14-08Initiated Banc of America Sec Neutral $7
Aug-06-08Reiterated Lazard Capital Buy $12 → $10
Aug-06-08Downgrade Canaccord Adams Buy → Hold
Jul-08-08Initiated Canaccord Adams Buy $7.30
Dec-07-07Reiterated Fortis Bank Hold $10 → $9
Sep-14-07Initiated Lazard Capital Buy $14
Sep-30-15 04:36PM  10 Best Nasdaq Biotech Stocks in the Third Quarter at TheStreet
Sep-29-15 02:46PM  4 Stocks Under $10 Making Big Moves Higher at TheStreet
01:03PM  Don't Panic! These 3 Beaten Down Biotech Stocks Are Now Great Buys at Motley Fool
Sep-28-15 09:37AM  Stocks to Watch: Alcoa, Apple, Cal-Maine, Media General at The Wall Street Journal
07:23AM  Two Kidney Cancer Drugs Show Promise in Separate Studies at The Wall Street Journal
Sep-26-15 12:30PM  Exelixis Inc Investor/Analyst Webcast to Review METEOR Data Call scheduled for 12:30 pm ET today
01:25AM  Two Kidney Cancer Drugs Show Promise in Separate Studies at The Wall Street Journal
Sep-25-15 06:09PM  Exelixis Announces Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Presented at European Cancer Congress 2015 Business Wire
06:02PM  Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer at TheStreet
06:01PM  Bristol-Myers Kidney Cancer Drug Boosts Survival in Big Study at Bloomberg
07:41AM  European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma Business Wire
Sep-24-15 08:00AM  Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, and Marketing to Support Commercialization of Cabozantinib and Cobimetinib Business Wire
Sep-22-15 05:08PM  Exelixis to Host Investor/Analyst Webcast During European Cancer Congress 2015 Business Wire
03:01PM  Enactment Of Clinton Prescription Drug Plan Will Result In R&D Job Losses at Forbes
Sep-15-15 07:00PM  Cramer: The surprising stock to buy if the Fed moves
06:55PM  Lightning Round: Perfect stock for young investors at CNBC
Sep-13-15 11:02AM  4 Ways to Protect Yourself From a Biotech Meltdown at Motley Fool
Aug-30-15 07:36AM  We Believe Healthcare's Next Biotech Buyout Target Is at Motley Fool
Aug-28-15 04:00PM  Exelixis Up on Swiss Approval of Advanced Melanoma Drug
Aug-27-15 12:29PM  Did Hedge Funds Sell Out Of Exelixis, Inc. (EXEL) Too Soon? Shares Jump On Regulatory Approval of Cobimetinib at Insider Monkey +7.98%
12:11PM  Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval at TheStreet
10:52AM  Here's Why Exelixis' Stock Briefly Gained 10% Today at Motley Fool
06:00AM  Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Business Wire
Aug-25-15 04:50PM  Exelixis' Cancer Drug Gets Breakthrough Therapy Status
01:04PM  EXELIXIS, INC. Financials
Aug-24-15 08:31AM  Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as Late-Breaker Presentation in Presidential Session at European Cancer Congress 2015 Business Wire
08:30AM  FDA Grants Breakthrough Therapy Designation to Exelixis Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy Business Wire
Aug-12-15 12:59PM  Make Room for Exelixis in Your Portfolio at Investopedia
12:02PM  3 Small-Cap Biopharma Stocks I'd Never Short at Motley Fool
09:30AM  Exelixis Posts Wider-Than-Expected Loss, Focus on Pipeline
03:35AM  Edited Transcript of EXEL earnings conference call or presentation 11-Aug-15 9:00pm GMT
Aug-11-15 05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:43PM  Exelixis reports 2Q loss
04:23PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:13PM  Exelixis Announces Second Quarter 2015 Financial Results and Provides Corporate Update Business Wire
04:10PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q2 2015 Exelixis Inc Earnings Release - After Market Close
Aug-06-15 02:20PM  5 Big FDA Decisions Expected in August at 24/7 Wall St. -6.21%
Aug-05-15 10:18AM  This Explains Exelixis' METEOR-ic Rise in July at Motley Fool -5.14%
08:51AM  Exelixis (EXEL) Shows Strength: Stock Adds 8.2% in Session - Tale of the Tape
Aug-03-15 07:29PM  Lightning Round: This stock is way oversold at CNBC +6.81%
Jul-29-15 04:36PM  What to Expect from Exelixis (EXEL) This Earnings Season? (revised) - Analyst Blog
06:46AM  Can the Rally in Exelixis (EXEL) Shares Continue? - Tale of the Tape
Jul-28-15 04:34PM  Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015
03:00PM  What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Jul-27-15 03:43PM  Exelixis (EXEL) Stock Falls on Upsized Secondary Offering at TheStreet
Jul-26-15 08:54AM  3 Biotech Stocks That Could Double Before 2016 at Motley Fool
Jul-24-15 04:39PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:45PM  How to Trade 4 of the Market's Most Active Stocks at TheStreet
Jul-23-15 08:08PM  Exelixis Prices Public Offering of Common Stock Business Wire -6.81%
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases
Jul-22-15 10:52AM  Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
09:54AM  Exelixis (EXEL) Stock Declines on Secondary Public Offering at TheStreet
Jul-21-15 06:40PM  Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
05:29PM  How Exelixis Used Good News to Raise Over $100 Million in New Capital at 24/7 Wall St.
04:01PM  Exelixis Launches Proposed Public Offering of Common Stock Business Wire
08:05AM  Potential Kidney Cancer Drugs Could Revolutionize Treatment at Motley Fool
04:51AM  Novartis bullish on Afinitor cancer drug despite new competition
Jul-20-15 05:24PM  EXELIXIS, INC. Files SEC form 8-K, Other Events +50.38%
04:11PM  Exelixis, Inc. (EXEL) Soars Following Cancer Drug Trial Data, But Competition Looms at Insider Monkey
02:33PM  Exelixis' Meteroric Rise From the Ashes at Motley Fool
12:03PM  Market Update: Monday's Mid-Day Movers; Greece Opens Banks; Gold Dwindles
10:50AM  Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer at Investor's Business Daily
10:35AM  Is Exelixis a Buyout Target Again? at 24/7 Wall St.
10:31AM  Why Exelixis, Inc.'s Stock Skyrocketed Today at Motley Fool
10:18AM  Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley Beats Q2 Views
09:38AM  Exelixis Up 50% After Meteroric METEOR Results
09:00AM  Exelixis shares surge 47% as kidney cancer drug trial yields positive results at MarketWatch
08:30AM  Exelixis Inc Conference Call to discuss the Results of Clinical Trial scheduled for 8:30 am ET today
07:02AM  Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech at Forbes
07:01AM  Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales at TheStreet
07:00AM  Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma Business Wire
Jul-16-15 06:50PM  Chart Week! Copper & gold +5.74%
09:01AM  3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double at Motley Fool
06:02AM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
01:32AM  Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer Business Wire
Jul-14-15 04:30PM  Exelixis' Cabozantinib in Phase I for Genitourinary Cancers - Analyst Blog
Jul-13-15 08:30AM  Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Business Wire
Jul-05-15 10:01AM  Exelixis to Investors: "Wait for It... No, Seriously, Wait for It!" at Motley Fool
Jul-02-15 04:00PM  Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog
Jul-01-15 06:21PM  Why Exelixis, Inc. Shares Slumped Today at Motley Fool -7.18%
11:23AM  10 Best Biotech Stocks in the NASDAQ at TheStreet
09:17AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat
08:45AM  Exelixis Provides Update on Genentechs Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound Business Wire
Jun-30-15 12:02PM  Small Cap Stocks to Watch in Biotech at Motley Fool +6.21%
Jun-26-15 06:01AM  Biotech Stock Mailbag: Exelixis, Puma Bio at TheStreet
Jun-25-15 10:30AM  5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Jun-22-15 09:32AM  Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape
Jun-20-15 11:31AM  Watch These 10 Stocks Over The Weekend
Jun-07-15 09:10AM  How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer at 24/7 Wall St.
Jun-06-15 12:21AM  ASCO Reaffirms Why I'm Holding Exelixis at Investopedia
Jun-01-15 02:06PM  Cancer drugmakers rally on upbeat prognosis at Financial Times +9.21%
12:31PM  Notable option activity in equities
09:40AM  6 Key Cancer Winners From ASCO Presentations at 24/7 Wall St.
May-31-15 09:00AM  Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer Business Wire
09:00AM  Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged Non-Small Cell Lung Cancers Business Wire
May-30-15 07:30AM  Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting Business Wire
May-28-15 04:37PM  EXELIXIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-22-15 06:42PM  5 Things Exelixis Management Wants You to Know at Investopedia
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.003,125078,730Nov 18 06:57 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.002,083037,237Nov 18 06:55 PM
BURKE DEBORAHSVP & Chief Financial OfficerNov 15Option Exercise0.006,438019,377Nov 18 06:52 PM